Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Sarcoma Clinical Trial

Official title:

A Phase I Trial of Lymphodepletion Plus Adoptive Cell Therapy With High-Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04052334
• Other study ID #: MCC-19837
• Secondary ID: 1K08CA252642-01
• Status: Completed
• Phase: Phase 1
• Start date: September 27, 2019
• Est. completion date: May 26, 2024

Study information

• Verified date: June 2024
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm trial that will evaluate the safety and feasibility of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: May 26, 2024
• Est. primary completion date: May 26, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

• Participants must fulfill all of the following criteria to be eligible for the study at the time of tumor resection and initiation of TIL expansion.

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Participants must have metastatic, high-grade soft tissue sarcoma, all subtypes will be eligible

• Residual measurable disease after resection of target lesion(s) for TIL growth

• Eastern Cooperative Oncology Group (ECOG) 0 to 1. ECOG performance status of 0 to 1 will be inferred if the patient's level of energy is = 50% of baseline.

• Participants must have progressed on at least one prior standard of care treatment regimen for metastatic disease.

• A negative pregnancy test (urine or serum) must be documented at screening for women of childbearing potential.

• A MUGA scan (ejection fraction > 50% is required) = 6 months prior to lymphodepletion.

• Pulmonary function tests should be completed = 6 months prior to lymphodepletion and forced expiratory volume (FEV1) > 65% or FVC > 65% of predicted are required

• Adequate renal, hepatic, and hematologic function, including creatinine of = 1.7 gm/dL, total bilirubin = 2.0 mg/dL, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dL, AST and ALT of less than 3 X institutional upper limit of normal, hemoglobin of 8 gm/dL or more, white blood cells of 3000 per mm^3 and total granulocytes of 1000 per mm^3 or more, and platelets of 100 000 per mm^3 or more.

• Participants must have a positive screening EBV antibody titre on screening test.

• Participants that have had previously grown sterile, validated TILs under good manufacturing practice conditions meeting the above criteria are eligible using the previously established TIL product stored in the Cell Therapies Core facility for up to 2 years after harvesting.

• Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the participant agrees to continue to use a method of contraception throughout the study such as: barrier (i.e. condom, diaphragm), hormonal, IUD, or sponge plus spermicide.

• Prothrombin time (PT) and partial thromboplastin time (PTT) within 1.5 times the institutional upper limit of normal

• Participants with echocardiogram (EKG) within 14 days of initiation of chemotherapy demonstrating no new rhythm, axis, or ST segment If new ST changes are present, patients may be included if cardiac stress test indicates no evidence of inducible cardiac ischemia.

• Urinalysis within 14 days demonstrating no evidence of a urinary tract infection.

• Participants with evidence of ongoing disease regression that is attributed to a therapy that is not part of the trial and that was administered after TIL harvest and expansion but prior to adoptive transfer of TILs should continue on prior therapy and may be treated with TIL only if their disease is stable or there is evidence of progressive disease. In this event as described above, the TIL will be frozen and stored for future use, in the event of progression, prior to the rapid expansion step.

Exclusion Criteria:

• Participants with active systemic infections requiring intravenous antibiotics, coagulation disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune system are excluded.

• Participants that have completed a chemotherapy regimen given with the intent of lymphodepletion or cellular immunotherapy which included non-myeloablative lymphodepletion strategy.

• Participants testing positive for HIV titer, hepatitis B surface antigen, human T-cell leukemia-lymphoma virus (HTLV) I or II antibody, or both rapid plasma regain (RPR) and fluorescent treponemal antibody (FTA) are excluded. Participants with hepatitis C antibody must have a negative (undetectable) viral load by polymerase chain reaction (PCR).

• Participants who are pregnant or nursing are excluded.

• Participants needing chronic immunosuppressive systemic steroids are excluded

• Participants with autoimmune diseases that require immunosuppressive medications are excluded

• Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe or contraindicated

• Participants with central nervous system metastases will be excluded.

• Inability to comprehend and give informed consent

Related Conditions & MeSH terms

• Sarcoma

Intervention

Drug:
• TIL
Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
• Interleukin-2
Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion.
• Fludarabine
Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
• Cyclophosphamide
Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion

Locations

Country	Name	City	State
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (4)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute	Iovance Biotherapeutics, Inc., National Cancer Institute (NCI), The V Foundation for Cancer Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Experienced Serious Adverse Events and Adverse Events	Participants able to safely tolerate preparatory lymphodepletion, infusion of tumor-infiltrating lymphocytes (TIL) and subsequent IL-2, as measured by adverse events and serious adverse events.	Baseline to 12 months
Secondary	Number of Participants With Objective Antitumor Response	Number of participants with objective response (Complete Response (CR) + Progressive Response (PR)) rate at 12 weeks following TIL infusion, as measured by RECIST v1.1	At 12 weeks
Secondary	Number of Participants With Circulating Tumor-infiltrating Lymphocytes (TIL) Product at 6 Weeks	Number of participants with persistence of TIL infusion product at 6 weeks following treatment, as measured by T-cell receptor repertoire comparison between the infusion product and circulating Peripheral blood mononuclear cell (PBMC).	At 6 weeks